GET DAILY SIGNALSCorteva (CTVA) Drops -31% Over 30 Days After Earnings Miss and Guidance Cut
Key Takeaways
- Corteva (CTVA) shares fell roughly 31% over the past 30 days, from $13.40 on October 14, 2026 to $9.19 on November 12, 2026.
- The move was driven by a third-quarter earnings miss and a cut to full-year 2026 guidance, including a 24.3% single-day decline on November 12.
- Brazil was the core problem: Latin America organic sales fell 31% as elevated channel inventories, farmer liquidity constraints, and pricing pressure intensified.
- Management lowered 2026 adjusted pro forma operating EBITDA guidance to $1.1–$1.125 billion, down from roughly $1.3 billion previously.
- The drop follows the October 1, 2026 spinoff of the seed business into Vylor, leaving CTVA as a more cyclical, pure-play crop protection company.
Company Overview and Recent Transformation
Corteva, Inc. is a global agricultural inputs company headquartered in Indianapolis, Indiana. Formed in 2019 through the spin-off of DowDuPont's agriculture division, the company is now focused on crop protection products—including herbicides, fungicides, insecticides, and biologicals—after completing the separation of its seed and genetics business into the separately traded company Vylor on October 1, 2026. Its portfolio includes brands such as Arylex (Rinskor), Pyraxalt, and Enlist. Investors follow CTVA closely for its exposure to global agricultural cycles, its R&D pipeline, and its competitive positioning against peers in the agrichemicals sector. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance Over the Past 30 Days and Quarter
Over the last 30 days, CTVA declined approximately 31%, from a closing price of $13.40 on October 14, 2026 to $9.19 on November 12, 2026—a drop of about $4.21 per share. Most of the decline came in a single session, when shares fell 24.3% on November 12 after third-quarter results missed expectations and full-year guidance was reduced.
The last quarter has been equally turbulent. The shares rallied in early October, peaking near $14.45 on October 7 shortly after the Vylor spinoff, before giving back those gains through late October and November. From a mid-August level of roughly $11.40, the stock is down about 19% on a trailing three-month basis, though the decline has been driven primarily by the sharp November selloff rather than a steady downtrend.
Earnings Miss and the Brazil Catalyst
The principal catalyst was Corteva's third-quarter 2026 report, released after the market close on November 11. Net sales fell 9% year over year to $1.591 billion, below consensus estimates near $1.76 billion, while adjusted pro forma operating earnings of $0.06 per share missed the $0.10 consensus. On a pro forma basis, continuing operations swung to a $54 million loss, and operating EBITDA declined 17% to $222 million.
The shortfall was concentrated in Latin America, where organic sales plunged 31%—volume down 24% and price down 7%—as elevated channel inventories, farmer liquidity constraints, and higher financing costs in Brazil suppressed purchasing. By contrast, North America, EMEA, and Asia Pacific all posted organic growth. Management cut full-year 2026 adjusted pro forma operating EBITDA guidance to $1.1–$1.125 billion and operating EPS to $0.76–$0.80, while announcing $130–$140 million in pre-tax restructuring charges tied to optimizing its crop protection manufacturing network. The company also declared its first quarterly dividend as a standalone company. From what I see, this earnings detail is important because it highlights the regional concentration of the issue.
Quarterly Context and Sector Pressures
The broader three-month trend reflects a structural transformation. The October 1 spinoff of the seed business removed Corteva's higher-margin, less-cyclical operations, leaving a crop protection-focused entity with greater sensitivity to agricultural cycles and to Brazil's downturn. The reorganized company also transitioned into a different index universe, adding pressure from repositioning investors. These dynamics were compounded by sector-wide weakness: peer FMC Corporation declined sharply on similar concerns about agrichemical pricing, underscoring a broader crop protection market downturn rather than a company-specific issue alone. I’m watching this closely as the spinoff effects continue to play out.
Key Factors to Watch Going Forward
Looking ahead, investors should monitor Corteva's fourth-quarter 2026 results and any 2027 outlook, particularly management's commentary on Brazil, where the company is reviewing its footprint, including potential restructuring or exit. Other key factors include U.S. acetochlor pricing pressure, generic competition on mature molecules, progress on the announced restructuring, and the trajectory of new-product volumes led by Arylex and Pyraxalt. Macroeconomic conditions—especially interest rates and farmer credit availability in Brazil—will remain central, as will any further changes to analyst estimates following the guidance reset.
Using AI Tools in My Research Process
In my ongoing analysis of names like CTVA, I frequently reference Tickeron’s AI Trend Prediction Engine to gauge potential directional shifts based on historical patterns and current data. It helps provide an additional layer of perspective when evaluating how sector-specific pressures might evolve.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Momentum Indicator for CTVA turns negative, indicating new downward trend
CTVA saw its Momentum Indicator move below the 0 level on November 12, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned negative. In 49 of the 78 cases, the stock moved further down in the following days. The odds of a decline are at 63%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CTVA turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 26 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.
CTVA moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CTVA crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 23 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 57%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Aroon Indicator for CTVA entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +2.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where CTVA advanced for three days, in 216 of 343 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
CTVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.316) is normal, around the industry mean (-0.492). P/E Ratio (7.778) is within average values for comparable stocks, (8.794). Projected Growth (PEG Ratio) (1.011) is also within normal values, averaging (0.867). Dividend Yield (0.026) settles around the average of (0.126) among similar stocks. CTVA's P/S Ratio (3.069) is slightly higher than the industry average of (1.476).
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. CTVA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company, which engages in the provision of agricultural products.
Industry ChemicalsAgricultural
Advertisement